Evidence map›Paper›PMID 41920367›Full record

ReviewAnnals of hematology2026

De novo mutations in ANK1 and SPTB cause hereditary spherocytosis: three case reports and literature review.

Yumei Qin, Liuting Lu, Xiaojing Huang, Wei Li, Yanming Qin, Shifu Tang, Shaojie Wei

Abstract readCase ReportsReview
In one paragraph

Review in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yumei Qin *Department of Laboratory Medicine, Key Laboratory of Precision Medicine for Viral Diseases, Guangxi Health Commission Key Laboratory of Clinical Biotechnology, Liuzhou People's Hospital, Liuzhou, 545006, China.
Liuting Lu *Department of Hematology, Liuzhou People's Hospital, Liuzhou, 545006, China.
Xiaojing HuangDepartment of Laboratory Medicine, Key Laboratory of Precision Medicine for Viral Diseases, Guangxi Health Commission Key Laboratory of Clinical Biotechnology, Liuzhou People's Hospital, Liuzhou, 545006, China.
Wei LiDepartment of Laboratory Medicine, Key Laboratory of Precision Medicine for Viral Diseases, Guangxi Health Commission Key Laboratory of Clinical Biotechnology, Liuzhou People's Hospital, Liuzhou, 545006, China.
Yanming QinDepartment of Laboratory Medicine, Key Laboratory of Precision Medicine for Viral Diseases, Guangxi Health Commission Key Laboratory of Clinical Biotechnology, Liuzhou People's Hospital, Liuzhou, 545006, China.
Shifu TangDepartment of Laboratory Medicine, Key Laboratory of Precision Medicine for Viral Diseases, Guangxi Health Commission Key Laboratory of Clinical Biotechnology, Liuzhou People's Hospital, Liuzhou, 545006, China. 24908210@qq.com.
Shaojie WeiDepartment of Laboratory Medicine, Guangxi Zhuang Autonomous Region Honorary Military Personnel Rehabilitation Hospital, No. 181, Rongjun Road, Liuzhou, Guangxi Zhuang Autonomous Region, 545005, China. 498561520@qq.com.

Funding

The self funded research project of the Health Commission of the Autonomous Region Z-B20241254
6 · The paper itself

Abstract

Hereditary spherocytosis (HS) is characterized primarily by jaundice, anemia, splenomegaly (enlarged spleen), increased numbers of spherocytes in peripheral blood, and elevated erythrocyte osmotic fragility. However, these manifestations are nonspecific, resulting in misdiagnosis or underdiagnosis. Here, we report three Chinese patients with a family history of HS. Case 1 was an infant who presented with jaundice and anemia during the neonatal period, without splenomegaly; case 2 was a woman with hepatitis C and mild anemia; and case 3 was a child with no obvious clinical symptoms. Genetic testing revealed a heterozygous ANK1 c.4429 C > T (p.Arg1477*) de novo mutation in case 1, a heterozygous ANK1 c.1025_1028dup (p.Val344Profs*13) de novo mutation in case 2, and a heterozygous SPTB c.5898 C > T (p.Gly1966 =) de novo variant in case 3. Interestingly, to the best of our knowledge, the ANK1 c.4429 C > T (p.Arg1477*) and c.1025_1028dup (p.Val344Profs*13) de novo mutations have not been previously reported in public mutation databases, extending the mutation spectrum of ANK1. Overall, HS should be considered in patients with unexplained jaundice or anemia, even in those without a family history. Clinicians should conduct genetic testing to establish a definitive diagnosis, guide treatment modalities, and provide genetic counseling to patients.

Indexed as

AnkyrinsMutationSpectrinSpherocytosis, HereditaryAdultChildFemaleHeterozygoteHumansInfantMaleANK1 protein, humanAnkyrinsSpectrinSPTB protein, humanANK1de novo mutationHereditary spherocytosisSPTB

Identifiers

PMID41920367
PMCPMC13043517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.